Rapid STI Testing Market (2026 - 2033)

Rapid STI Testing Market Summary

The global rapid STI testing market size was valued at USD 1.5 billion in 2025 and is projected to grow from USD 1.6 billion in 2026 to USD 2.8 billion by 2033, at a CAGR of 8.7% from 2026 to 2033. North America dominated the market, accounting for a revenue share of 41.1% in 2025. Market growth is primarily driven by the rising global burden of sexually transmitted infections, which is increasing demand for rapid, accessible, and timely diagnostic testing

Source: Grand View Research, IR Documents, Primary Interviews, Paid Databases

To learn more about this report, Download Free Sample Report

To learn more about this report, Download Free Sample Report

Market Dynamics

Market Concentration & Characteristics

The rapid STI testing market demonstrates a high degree of innovation, supported by advancements in molecular self-testing and decentralized diagnostic technologies. In January 2026, OraSure Technologies submitted an FDA application for a rapid molecular self-test targeting Chlamydia trachomatis and Neisseria gonorrhoeae, alongside its Colli-Pee at-home urine collection device. The development integrates molecular detection with self-testing and decentralized specimen collection, minimizing dependence on conventional laboratory workflows. These advancements are expected to enhance testing accessibility, privacy, and convenience while supporting the market’s transition toward patient-centric, rapid, and home-based STI diagnostic solutions.

The rapid STI testing market demonstrates a low level of M&A activity, with limited acquisition activity specifically targeting rapid STI diagnostic technologies. In December 2024, OraSure Technologies acquired Sherlock Biosciences, whose lead product included a rapid molecular self-test for chlamydia and gonorrhea, strengthening OraSure’s rapid STI diagnostics portfolio. The transaction involved an initial aggregate purchase price of US$28.35 million, with additional contingent consideration of up to USD 20 million. The transaction highlights strategic interest in rapid molecular STI diagnostics; however, the limited number of comparable acquisitions indicates that market development remains primarily driven by product innovation, partnerships, and commercialization initiatives.

To learn more about this report, Download Free Sample Report

Regulations have a significant impact on the rapid STI testing market, influencing product development, clinical validation, commercialization, and adoption across healthcare settings. Stringent regulatory requirements for analytical performance, clinical accuracy, safety, quality management, and labeling can extend development timelines and increase compliance costs. Requirements for regulatory clearance or approval may also affect the deployment of rapid molecular and self-testing technologies. In addition, evolving standards for decentralized and over-the-counter diagnostics can shape manufacturers’ commercialization strategies, while regulatory harmonization across countries may facilitate broader market access and international expansion.

Product expansion is strengthening the rapid STI testing market as manufacturers broaden test menus, target additional pathogens, and develop solutions suited to decentralized testing environments. Expansion toward multiplex molecular assays enables simultaneous detection of multiple infections while reducing testing time and improving diagnostic efficiency. Manufacturers are also developing self-testing and near-point-of-care formats to address demand for convenient testing outside centralized laboratories. Broader specimen compatibility, simplified workflows, and integration with digital result-management tools further enhance product utility. These developments are expanding the range of rapid STI testing applications across clinics, pharmacies, community settings, and home-based testing environments.

Regional expansion is creating new growth opportunities in the rapid STI testing market, particularly across regions where centralized laboratory infrastructure and access to timely diagnostics remain limited. Manufacturers are extending molecular and rapid testing solutions into decentralized healthcare networks, community-based programs, pharmacies, and home-testing channels. Expansion across emerging markets is supported by the need for affordable, accessible, and faster STI diagnosis, while developed markets are witnessing broader adoption of near-point-of-care and self-testing technologies. Increasing regulatory alignment, local partnerships, distribution networks, and investments in diagnostic infrastructure are further supporting commercialization and geographic penetration of rapid STI testing solutions.

Analyst Perspective

The rapid STI testing market is positioned for sustained growth as healthcare systems increasingly prioritize timely diagnosis, decentralized testing, and improved patient accessibility. Advances in rapid molecular diagnostics, multiplex assays, self-testing, and simplified sample collection are reducing dependence on centralized laboratory workflows and supporting faster clinical decision-making. Growing STI testing requirements and expansion of community- and home-based testing are expected to strengthen market adoption. North America and Europe remain key markets due to established diagnostic infrastructure, while Asia Pacific offers significant growth potential. However, regulatory requirements, affordability constraints, and variable access to quality-assured rapid tests may influence commercialization and adoption across emerging markets.

Technology Insights

The molecular diagnostics / naat segment accounted for the largest share of 50.2% and is expected to register the fastest growth in the rapid STI testing market Its strong position is supported by high analytical sensitivity and specificity, multiplex pathogen detection, shorter turnaround times, and increasing deployment of molecular technologies in decentralized testing environments. In January 2025, Roche received FDA 510(k) clearance and CLIA waiver for its cobas liat sexually transmitted infection assay panels, including CT/NG and CT/NG/MG configurations. The real-time PCR assays provide results in approximately 20 minutes and support testing of urine and vaginal swab specimens. The availability of rapid, automated molecular platforms is strengthening same-visit testing capabilities and supporting broader adoption of NAAT-based STI diagnostics across point-of-care settings.

The rapid Immunoassays segment is expected to grow at a lucrative CAGR over the forecast period, supported by short turnaround times, simple workflows, low equipment requirements, and suitability for decentralized STI screening. In August 2026, Health Canada approved MedMira’s Reveal TP (Syphilis) Antibody Test, a rapid immunoassay designed for point-of-care detection of Treponema pallidum antibodies. Health Canada lists the product as a licensed Class III test kit. WHO reported in 2025 that approximately 8 million adults aged 15-49 acquired syphilis in 2022, while rapid tests can enable treatment initiation during the same clinical visit. These advantages are expected to support continued adoption of rapid immunoassays across clinics, community programs, and other near-patient settings.

Infection Type

The syphilis segment dominated the global rapid STI testing market, accounting for 27.8% of the revenue share in 2025. Its leading position is supported by the substantial disease burden, widespread use of rapid antibody-based screening, and growing integration of syphilis testing into antenatal and decentralized healthcare programs. In July 2025, WHO prequalified Abbott’s Determine Antenatal Care Panel, the first bundled rapid diagnostic panel for simultaneous screening of syphilis, HIV, and hepatitis B using capillary whole blood, strengthening integrated syphilis screening in resource-limited settings. WHO estimated 8 million new syphilis infections among adults aged 15-49 in 2022, alongside approximately 700,000 congenital syphilis cases, highlighting the substantial unmet testing requirement. These factors are expected to sustain demand for rapid syphilis testing across clinical, community, and antenatal settings.

The mycoplasma genitalium segment is expected to demonstrate the fastest growth, with a CAGR of 12.5% over the forecast period, supported by increasing clinical recognition of the infection, growing availability of molecular diagnostics, and the need for accurate detection to guide treatment amid antimicrobial resistance concerns. In May 2026, COWIN GENE launched the Cowingene MG/MH NATBox, a rapid molecular diagnostic solution designed for detection of Mycoplasma genitalium and Mycoplasma hominis. The development expands the availability of targeted nucleic acid-based testing for genital mycoplasma infections. In addition, the CDC identifies M. genitalium as an important cause of urethritis and estimates that it accounts for approximately 15%-20% of nongonococcal urethritis cases among men, supporting the need for expanded diagnostic testing and targeted disease management.

Test Type Insights

The single-target tests segment dominated the global rapid STI testing market, accounting for 63.1% of the revenue share in 2025. Its leading position is supported by established clinical use, simplified workflows, lower testing complexity, and widespread availability of pathogen-specific assays for infections such as syphilis, chlamydia, and gonorrhea. Single-target tests remain particularly relevant in screening programs where testing is directed toward a specific suspected infection and rapid clinical decision-making is required. Their relatively simple test formats, ease of interpretation, and compatibility with decentralized testing settings further support adoption. In addition, the substantial global burden of individual STIs continues to sustain demand for pathogen-specific testing, particularly for syphilis, where rapid antibody-based assays are widely used across clinical, antenatal, community, and point-of-care screening programs.

The multiplex/combination tests segment is expected to demonstrate the fastest growth, with a CAGR of 11.1% over the forecast period, supported by the ability to detect multiple STI pathogens from a single specimen, improve diagnostic efficiency, and reduce the need for sequential testing. In January 2025, Kryptos Biotechnologies and Osang Healthcare announced the development of a rapid multiplex molecular STI test based on the portable KUICK platform. The real-time qPCR-based assay is being developed to simultaneously detect chlamydia, gonorrhea, and trichomoniasis from vaginal swab or urine specimens, with testing targeted within 30 minutes. The RIGHT Foundation committed approximately KRW 1.78 billion to the project, highlighting investment in rapid multiplex STI diagnostics for decentralized settings.

Sample Type Insights

The swab specimens segment dominated the global rapid STI testing market, accounting for 37.8% of the revenue share in 2025, and is expected to register the fastest CAGR of 9.5%. Growth is supported by the suitability of vaginal, cervical, rectal, and oropharyngeal swabs for molecular and rapid STI testing, along with increasing acceptance of self-collection. In March 2025, FIND sought a manufacturing and commercialization partner for its low-cost fluorescence-based rapid antigen test for Neisseria gonorrhoeae, designed to use vaginal swabs in women and urine in men; the device had reached design freeze and was ready for technology transfer. Clinical evidence also indicates that vaginal swabs are an optimal specimen type for STI testing among women, supporting their continued use across decentralized and point-of-care testing pathways.

The whole blood/serum/plasma segment is expected to demonstrate lucrative growth over the forecast period, supported by the established use of blood-based specimens for rapid serological detection of syphilis and other sexually transmitted infections, particularly across antenatal, community, and point-of-care screening programs. In 2026, WHO prequalified Abbott’s Determine Syphilis Advanced, an immunochromatographic lateral-flow assay for syphilis, highlighting continued advancement of rapid blood-based STI diagnostics. WHO documentation also confirms the availability of rapid combination assays capable of detecting Treponema pallidum antibodies using serum, plasma, and venous or capillary whole blood. The compatibility of these specimens with simple rapid-testing workflows is expected to support broader screening and near-patient STI testing.

End Use Insights

The diagnostic laboratories & near-point-of-care facilities segment is expected to account for the largest share of 34.1% of the rapid STI testing market, supported by high testing volumes, established diagnostic infrastructure, availability of trained personnel, and increasing integration of rapid molecular platforms into decentralized laboratory workflows. In June 2025, Linear Diagnostics secured approximately £1 million in funding from the UK National Institute for Health and Care Research (NIHR) to advance its rapid molecular STI testing technology, which is being developed to detect infections such as chlamydia and gonorrhoea in as little as five minutes. The development highlights continued investment in near-patient molecular diagnostics designed to shorten turnaround times and enable earlier clinical decision-making, supporting adoption across diagnostic laboratories and near-point-of-care facilities.

To learn more about this report, Download Free Sample Report

The home/self-testing segment is expected to see the fastest growth, driven by rising demand for privacy, convenience, self-collection, and reduced reliance on clinic-based testing. In March 2025, the U.S. FDA granted De Novo marketing authorization to the Visby Medical Women’s Sexual Health Test, the first over-the-counter test capable of detecting chlamydia, gonorrhea, and trichomoniasis entirely at home. The PCR-based test uses a self-collected vaginal swab and provides results in approximately 30 minutes. Clinical evaluation demonstrated positive agreement of 97.2% for chlamydia, 100% for gonorrhea, and 97.8% for trichomoniasis. The availability of fully at-home molecular diagnostics is expected to improve access to testing and support rapid expansion of the segment.

Regional Insights

North America dominated the global rapid STI testing market and accounted for the largest revenue share of 41.1% in 2025, supported by advanced diagnostic infrastructure, established screening programs, and increasing adoption of molecular and point-of-care testing technologies. Regional market growth is further supported by the expansion of self-collection and decentralized testing approaches to improve diagnostic accessibility. In Canada, the iStatis Syphilis Antibody Test provides results within 15 minutes and is intended for near-patient testing across healthcare facilities. In addition, Canadian screening recommendations published in 2026 highlighted the potential of point-of-care, self-testing, and rapid testing approaches to improve testing acceptability and uptake. These factors are strengthening access to timely STI diagnosis and supporting broader adoption of rapid diagnostic solutions across North America.

To learn more about this report, Download Free Sample Report

U.S. Rapid STI Testing Market Trends

The U.S. accounted for the largest share of the North America rapid STI testing market, supported by advanced diagnostic infrastructure, substantial STI testing volumes, and increasing adoption of point-of-care and self-testing solutions. In October 2024, Labcorp expanded its STI testing portfolio through an agreement with NOWDiagnostics to exclusively distribute the FDA-authorized First to Know Syphilis Test to healthcare providers nationwide. The fingerstick blood test delivers results within 15 minutes and supports use across clinical and home-based settings. Labcorp reported conducting more than 5.5 million syphilis tests annually, with testing volumes more than doubling over the preceding decade. The expanding availability of rapid diagnostic solutions through established distribution networks is expected to improve testing accessibility and support timely STI detection across the U.S.

Europe Rapid STI Testing Market Trends

Europe represents a significant market for rapid STI testing, supported by established sexual health services, comprehensive disease surveillance, and growing demand for decentralized and multiplex diagnostic solutions. In July 2025, France-based MagIA Diagnostics launched the MAGESTICS project, in collaboration with INFYNITY BIOMARKERS and Grenoble Alpes University Hospital, to expand its MforScreen platform toward simultaneous detection of syphilis, chlamydia, and gonorrhea, complementing its existing viral STI screening capabilities. The initiative reflects increasing regional emphasis on integrated STI diagnostic platforms and broader testing coverage. In addition, ECDC reported 213,443 chlamydia, 106,331 gonorrhea, and 45,577 syphilis cases in the EU/EEA in 2024, highlighting the substantial diagnostic burden and supporting continued demand for accessible and timely STI testing solutions across Europe.

The UK rapid STI testing market is supported by well-established sexual health services, expanding self-sampling pathways, and increasing demand for convenient and timely diagnostic solutions. In 2025, Randox Health offered rapid STI urine screening through its London clinics, covering 10 common STIs, including chlamydia and gonorrhoea, with expedited laboratory testing and result delivery. According to UKHSA, England recorded 334,151 new STI diagnoses in 2025, including 151,163 chlamydia and 63,943 gonorrhoea diagnoses. Approximately 8.9 million STI tests were conducted during the year, while 42.2% of sexual health consultations were delivered online. High testing volumes and increasing integration of digital sexual health services are expected to support continued adoption of rapid and decentralized STI testing solutions across the UK.

The Germany rapid STI testing market is expected to represent a significant growth, supported by established laboratory infrastructure, specialized STI diagnostic networks, and increasing demand for timely molecular and point-of-care testing. In 2025, the Robert Koch Institute strengthened STI surveillance through molecular characterization of Neisseria gonorrhoeae and Chlamydia trachomatis, supporting evidence-based approaches to diagnosis and antimicrobial-resistance monitoring. The diagnostic requirement remains substantial, with 9,519 syphilis cases reported in Germany in 2024, representing a 3.9% increase from 2023 and a record high, while the national incidence reached 11.2 cases per 100,000 population. Continued STI surveillance, coupled with the need for earlier diagnosis and treatment, is expected to support adoption of rapid and decentralized STI testing solutions across Germany.

Asia Pacific Rapid STI Testing Market Trends

The rapid STI testing industry in the Asia Pacific is anticipated to grow at the fastest CAGR from 2026 to 2033. Asia Pacific is expected to register strong growth in the rapid STI testing market, supported by a substantial STI burden, disparities in access to centralized laboratory services, and increasing adoption of decentralized diagnostic approaches. WHO estimates indicate approximately 86 million new cases of chlamydia, gonorrhoea, syphilis, and trichomoniasis in the Western Pacific Region in 2020, underscoring the significant regional testing requirement. In Australia, the government-supported Test, Treat and Go (TTANGO) program incorporates molecular point-of-care testing for chlamydia, gonorrhoea, and trichomoniasis in remote Aboriginal and Torres Strait Islander communities. Australia also reported 155,681 notifiable STI cases in 2024. Continued expansion of near-patient testing programs is expected to improve diagnostic accessibility and support timely STI detection and treatment across the region.

The China rapid STI testing market represents a high-potential, supported by a substantial STI burden, expanding molecular diagnostic capabilities, and growing demand for timely and decentralized testing solutions. In April 2025, Sinopharm subsidiary Shanghai GeneoDx received NMPA Class III medical device registration for a PCR-based assay designed for simultaneous detection of Treponema pallidum and herpes simplex virus types I and II, strengthening the availability of multiplex molecular STI diagnostics. The underlying diagnostic requirement remains significant, with China CDC reporting 52,197 syphilis cases and 10,547 gonorrhea cases in December 2025. Continued advancement of molecular testing technologies, regulatory authorization of multiplex assays, and sustained STI testing requirements are expected to support market expansion and broader adoption of rapid diagnostic solutions across China.

The Japan rapid STI testing market is an important market, supported by advanced healthcare infrastructure, sophisticated diagnostic laboratories, and established infectious disease surveillance systems. The diagnostic requirement remains significant, particularly for syphilis, with Japan’s Ministry of Health, Labour and Welfare reporting that annual syphilis notifications have exceeded 10,000 cases since 2022, with elevated levels continuing in provisional 2025 data. In November 2025, Japan revised its national STI prevention guidelines in response to the expansion of syphilis and congenital syphilis, emphasizing strengthened testing and consultation systems, healthcare provision, surveillance, and research and development. These public-health measures, combined with Japan’s established diagnostic capabilities, are expected to support greater adoption of timely, accessible, and decentralized rapid STI testing solutions.

Latin America Rapid STI Testing Market Trends

Latin America represents an emerging market for rapid STI testing, supported by a substantial STI burden, expanding public health screening programs, and increasing emphasis on decentralized diagnostic access. In 2025, PAHO introduced regional recommendations to strengthen syphilis testing and treatment, emphasizing expanded screening through primary healthcare and diversified approaches, including rapid and self-testing strategies. PAHO estimated approximately 4.2 million new syphilis cases in the Americas in 2024, representing a 15% increase from 2022, with 90% of these cases concentrated in Latin America and the Caribbean. The substantial disease burden, coupled with regional initiatives to expand timely diagnosis, is expected to support greater adoption of affordable and accessible rapid STI testing solutions across Latin America.

Middle East and Africa Rapid STI Testing Market Trends

The Middle East & Africa rapid STI testing market is expected to develop gradually, supported by improving diagnostic infrastructure, expansion of community-based screening programs, and increasing adoption of point-of-care testing across resource-constrained settings. In July 2025, WHO issued updated STI service-delivery recommendations emphasizing decentralization, service integration, task sharing, and digital health approaches to improve access to STI prevention, diagnosis, and treatment. In September 2025, WHO also reported that more than 1 million curable STIs are acquired globally each day, while access to molecular testing for chlamydia and gonorrhoea remains limited across many low- and middle-income countries. Continued expansion of decentralized healthcare services and affordable rapid diagnostic technologies is expected to improve testing accessibility and support market development across the Middle East & Africa.

Key Rapid STI Testing Company Insights

The rapid STI testing market is characterized by the presence of established diagnostic companies and specialized manufacturers competing through product innovation, diagnostic performance, and expanded point-of-care capabilities. Key market participants include Danaher Corporation, F. Hoffmann-La Roche Ltd., Abbott, Visby Medical, Inc., SD Biosensor, INC., Premier Medical, bioLytical Laboratories Inc., Biosynex SA, Trinity Biotech plc, Guangzhou Wondfo Biotech Co., Ltd., InTec Products, Inc., and Access Bio, Inc. These companies are strengthening their competitive positions through molecular diagnostic platforms, rapid immunoassays, multiplex testing solutions, and self-testing products. Continued investment in decentralized diagnostics, regulatory approvals, product portfolio expansion, and broader distribution networks is expected to support competitive development across the market.

Key Rapid STI Testing Companies

The following key companies have been profiled for this study on the rapid STI testing market.

• Danaher Corporation

• F. Hoffmann-La Roche Ltd

• Abbott

• Visby Medical, Inc.

• SD Biosensor, INC

• Premier Medical

• bioLytical Laboratories Inc.

• Biosynex SA

• Trinity Biotech plc

• Guangzhou Wondfo Biotech Co., Ltd.

• InTec Products, Inc.

• Access Bio, Inc.

Recent Developments

• In January 2025, Roche received U.S. FDA 510(k) clearance and CLIA waiver for its cobas liat CT/NG and CT/NG/MG STI multiplex assay panels. The PCR-based assays enable simultaneous detection and differentiation of chlamydia, gonorrhea, and Mycoplasma genitalium, providing results in 20 minutes or less for point-of-care testing.

• In March 2025, Visby Medical received U.S. FDA De Novo marketing authorization for its Women’s Sexual Health Test, the first over-the-counter diagnostic test for chlamydia, gonorrhea, and trichomoniasis that can be performed entirely at home. The test uses a self-collected vaginal swab and provides results in approximately 30 minutes.

• In 2026, COWIN GENE launched the Cowingene MG/MH NATBox Detection Kit, a molecular point-of-care diagnostic solution for rapid detection of Mycoplasma genitalium and Mycoplasma hominis. The assay supports urine, urethral, cervical, and vaginal-swab specimens and operates with the compact NATBox Mini II platform, strengthening decentralized STI testing capabilities.

• In May 2026, AAZ and En Carta Diagnostics entered into a co-development and commercialization agreement to develop rapid molecular tests and self-tests for chlamydia and gonorrhea. The tests are designed to provide results in under 30 minutes and enable decentralized testing across primary care, pharmacies, and home settings in Europe.

Global Rapid STI Testing Market Report Segmentation

This report forecasts revenue growth at country levels and provides an analysis on the latest industry trends and opportunities in each of the sub-segments from 2021 to 2033. For the purpose of this study, Grand View Single-target Tests has segmented the Rapid STI testing market report on the basis of technology, infection type, test type, sample type, end use and region.

• Technology Outlook (Revenue, USD Million, 2021 - 2033)

  • Molecular Diagnostics / NAAT

  • Rapid Immunoassays

  • Others

• Infection Type Outlook (Revenue, USD Million, 2021 - 2033)

  • Chlamydia

  • Gonorrhea

  • SYPHILIS

  • TRICHOMONIASIS

  • Mycoplasma genitalium

  • Multiple STI Targets

  • Other STI Targets

• Test Type Outlook (Revenue, USD Million, 2021 - 2033)

  • Single-target Tests

  • Multiplex / Combination Tests

• Sample Type Outlook (Revenue, USD Million, 2021 - 2033)

  • Urine

  • Swab Specimens

  • Whole Blood / Serum / Plasma

  • Other Specimens

• End Use Outlook (Revenue, USD Million, 2021 - 2033)

  • Hospitals & Clinics

  • Diagnostic Laboratories & Near-Point-of-Care Facilities

  • Public Health & Community Testing Settings

  • Home / Self-testing

  • Other End Uses

• Rapid STI Testing Market Regional Outlook (Revenue, USD Million; 2021 - 2033)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Norway

    • Denmark

    • Sweden

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Thailand

  • Latin America

    • Brazil

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait

Research Methodology

The rapid STI testing market figures in this report are based on a proven research process that combines executive interviews with secondary research from proprietary databases, company filings, and recognized regulatory and institutional sources. Market size is built through value-chain sizing - reconciling supply-side and demand-side estimates - and triangulated with bottom-up and top-down approaches. Every estimate passes multiple levels of expert validation before publication, with each rapid STI testing segment quantified using the revenue-capture definitions in the table below.

Estimation Model

The rapid STI testing market was estimated by identifying key manufacturers, benchmarking major rapid STI testing products, and assessing product-level revenues across molecular diagnostics, immunoassays, and other technologies. Market estimates were further validated using existing market size, testing uptake/patient share, technology-level revenues, and key manufacturers’ market shares to derive the overall market size.

Delivered Customizations

This report has been delivered with the following In-depth customizations